Health• Updated
Supreme Court Questions Huge Gap in Cancer Drug Prices
Reported by Kavya Rao (Senior Writer) · The Hindu - Health ·
Confirmed by a second source: Bing News - Health (India)
UPDATE - follow-up to Who decides the cost of medicines in India?: A cancer medicine supplied to a retailer for ₹2,700 carries a maximum retail price of ₹27,000, prompting the Supreme Court to question the massive gap in September 2026.
Trade Margin Cap
Following this scrutiny, the National Pharmaceutical Pricing Authority announced a 30% cap on trade margins for 137 anti-cancer drugs, which took effect on November 9. This intervention could lower prices significantly for patients buying certain products.
Context
India's drug price controls trace back to the Defence of India Act during the 1962 Sino-Indian War. Balancing medicine licensing under the Central Drugs Standard Control Organisation and pricing under the pricing authority remains a key policy challenge.
What changed since yesterday
- Supreme Court Questions Drug Price Gap as India Caps Cancer Medicine Margins
- New price caps on cancer drugs follow Supreme Court questions
Latest
Supreme Court Questions Huge Gap in Cancer Drug Prices
ExplainerWhy this matters
What Happened
The Supreme Court questioned the large price gap between what retailers pay for cancer medicines and what patients are charged, leading the National Pharmaceutical Pricing Authority to cap trade margins at 30% for 137 anti-cancer drugs.
Why It Matters
High medicine prices place a heavy financial burden on patients and their families, especially for critical illnesses like cancer. Capping trade margins directly limits excessive markups by the supply chain, making essential treatments more affordable.
What Happens Next
Authorities will monitor the implementation of the new caps starting November 9, while policymakers continue to evaluate how better coordination between drug licensing and pricing bodies can address broader healthcare costs.
More in Health
Health• UpdatedSource: The HinduWorth knowing
WHO report shows drop in India's TB death rate as numbers face review
Reported by Manish Reddy (Senior Writer) · The Hindu - Health ·
